Parkinson's cases are set to double by 2050. Learn why it's rising and how lifestyle changes can support long-term brain ...

Global Parkinson’s disease cases are projected to more than double to 25.2 million by 2050, driven largely by aging ...

Initiation of dosing in our Phase 1b clinical trial represents an important step in the clinical development of GT-02287 and in Gain’s mission to deliver a disease-modifying therapy to people with ...

Mar. 9, 2025 — A recently launched Phase 1 clinical trial is examining the safety and feasibility of a groundbreaking treatment approach for Parkinson's disease in which a patient's stem cells ...

For people with a certain sleep disorder, a simple blood test could help predict the development of dementia years before ...

Teleneurorehabilitation provides similar improvement in motor and nonmotor symptoms for patients with Parkinson’s disease as ...

New Jersey lawyer Harvey Silikovitz was diagnosed with Parkinson’s disease in 2019 but was determined to fulfill his dream of ...

The research findings primarily focus on individuals with a sleep disorder but may have broader implications. A recent study ...

Researchers have discovered more about PINK1, a protein that’s directly tied to Parkinson’s disease. A team from Walter and Eliza Hall Institute in Australia has shown how the protein attaches to cell ...

WEHI researchers have made a huge leap forward in the fight against Parkinson's disease, solving a decades-long mystery that paves the way for development of new drugs to treat the condition.

Gain Therapeutics (GANX) announced the dosing of the first participant with Parkinson’s disease in its Phase 1b clinical trial of GT-02287, the ...